Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics' Q1 Loss Nearly Doubles

NEW YORK (GenomeWeb News) – Rosetta Genomics today reported that its first-quarter net loss nearly doubled year over year as the firm gears up for initial diagnostic product launches.
The Rehovot, Israel-based firm had no revenues for the three-month period ended March 31. The firm expects to have its initial microRNA-based diagnostic tests for cancer approved for use in CLIA labs by the end of this year.
Specifically, it plans to seek regulatory approval later this year for CLIA tests for cancer of unknown primary and for differentiating between mesothelioma and adenocarcinoma.
Rosetta’s net loss increased to $3.9 million, or $.33 per share, from $2 million, or $.23 per share, in the first quarter of 2007.
The firm’s R&D expenses doubled to $2.4 million from $1.2 million, and its costs for marketing, business development, and general and administrative functions rose 26.4 percent to $1.34 million from $1.06 million.
Rosetta finished the quarter with $9.5 million in cash and cash equivalents.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.